218 related articles for article (PubMed ID: 33493595)
1. Development of nanoparticle-based orodispersible palatable pediatric formulations.
Deng Y; Shen L; Yang Y; Shen J
Int J Pharm; 2021 Mar; 596():120206. PubMed ID: 33493595
[TBL] [Abstract][Full Text] [Related]
2. Development and in vivo evaluation of child-friendly lopinavir/ritonavir pediatric granules utilizing novel in situ self-assembly nanoparticles.
Pham K; Li D; Guo S; Penzak S; Dong X
J Control Release; 2016 Mar; 226():88-97. PubMed ID: 26849919
[TBL] [Abstract][Full Text] [Related]
3. Novel in situ self-assembly nanoparticles for formulating a poorly water-soluble drug in oral solid granules, improving stability, palatability, and bioavailability.
Guo S; Pham K; Li D; Penzak SR; Dong X
Int J Nanomedicine; 2016; 11():1451-60. PubMed ID: 27103803
[TBL] [Abstract][Full Text] [Related]
4. Comparative Bioavailability of Two Formulations of Biopharmaceutical Classification System (BCS) Class IV Drugs: A Case Study of Lopinavir/Ritonavir.
Saeed AM; Schmidt JM; Munasinghe WP; Vallabh BK; Jarvis MF; Morris JB; Mostafa NM
J Pharm Sci; 2021 Dec; 110(12):3963-3968. PubMed ID: 34530003
[TBL] [Abstract][Full Text] [Related]
5. Statistical modeling, optimization and characterization of solid self-nanoemulsifying drug delivery system of lopinavir using design of experiment.
Patel G; Shelat P; Lalwani A
Drug Deliv; 2016 Oct; 23(8):3027-3042. PubMed ID: 26882014
[TBL] [Abstract][Full Text] [Related]
6. Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients.
Salerno SN; Capparelli EV; McIlleron H; Gerhart JG; Dumond JB; Kashuba ADM; Denti P; Gonzalez D
Pharmacotherapy; 2023 Jul; 43(7):638-649. PubMed ID: 35607886
[TBL] [Abstract][Full Text] [Related]
7. A hybrid design to optimize preparation of lopinavir loaded solid lipid nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir coformulation.
Ravi PR; Vats R; Dalal V; Murthy AN
J Pharm Pharmacol; 2014 Jul; 66(7):912-26. PubMed ID: 24697749
[TBL] [Abstract][Full Text] [Related]
8. Development of Oral Flexible Tablet (OFT) Formulation for Pediatric and Geriatric Patients: a Novel Age-Appropriate Formulation Platform.
Chandrasekaran P; Kandasamy R
AAPS PharmSciTech; 2017 Aug; 18(6):1972-1986. PubMed ID: 27921260
[TBL] [Abstract][Full Text] [Related]
9. Development of Spray-Dried Cyclodextrin-Based Pediatric Anti-HIV Formulations.
Ivone R; Fernando A; DeBoef B; Meenach SA; Shen J
AAPS PharmSciTech; 2021 Jun; 22(5):193. PubMed ID: 34184163
[TBL] [Abstract][Full Text] [Related]
10. QbD based development of proliposome of lopinavir for improved oral bioavailability.
Patel GM; Shelat PK; Lalwani AN
Eur J Pharm Sci; 2017 Oct; 108():50-61. PubMed ID: 27586019
[TBL] [Abstract][Full Text] [Related]
11. Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug.
Nassar T; Rohald A; Naraykin N; Barasch D; Amsalem O; Prabhu P; Kotler M; Benita S
J Drug Target; 2019; 27(5-6):590-600. PubMed ID: 30470150
[TBL] [Abstract][Full Text] [Related]
12. Design, development and in-vitro evaluation of diclofenac taste-masked orodispersible tablet formulations.
Guhmann M; Preis M; Gerber F; Pöllinger N; Breitkreutz J; Weitschies W
Drug Dev Ind Pharm; 2015 Apr; 41(4):540-51. PubMed ID: 24495274
[TBL] [Abstract][Full Text] [Related]
13. Solid self-microemulsifying drug delivery system of ritonavir.
Deshmukh A; Kulkarni S
Drug Dev Ind Pharm; 2014 Apr; 40(4):477-87. PubMed ID: 23465049
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability enhancement of a BCS IV compound via an amorphous combination product containing ritonavir.
Miller DA; Keen JM; Brough C; Ellenberger DJ; Cisneros M; Williams RO; McGinity JW
J Pharm Pharmacol; 2016 May; 68(5):678-91. PubMed ID: 26454138
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
[TBL] [Abstract][Full Text] [Related]
16. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
[TBL] [Abstract][Full Text] [Related]
17. Development of In Situ Self-Assembly Nanoparticles to Encapsulate Lopinavir and Ritonavir for Long-Acting Subcutaneous Injection.
Tanaudommongkon I; Tanaudommongkon A; Dong X
Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34207272
[TBL] [Abstract][Full Text] [Related]
18. Drug Formulations: Standards and Novel Strategies for Drug Administration in Pediatrics.
Thabet Y; Klingmann V; Breitkreutz J
J Clin Pharmacol; 2018 Oct; 58 Suppl 10():S26-S35. PubMed ID: 30248193
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
Simpson KN; Jones WJ; Rajagopalan R; Dietz B
Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124
[TBL] [Abstract][Full Text] [Related]
20. Combination lopinavir and ritonavir alter exogenous and endogenous bile acid disposition in sandwich-cultured rat hepatocytes.
Griffin LM; Watkins PB; Perry CH; St Claire RL; Brouwer KL
Drug Metab Dispos; 2013 Jan; 41(1):188-96. PubMed ID: 23091188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
